Significant effect of Diamyd[®] in Type 1 diabetes shown in a new comprehensive analysis of previous Phase III and Phase II trials

Diamyd Medical announces that a new analysis based on data from more than 530 individual patients from previous phase III and II trials in Europe and US with the diabetes vaccine Diamyd[® ]has identified genetically defined subgroups of type 1 diabetes patients that show a positive and statistically significant dose-dependent treatment response.In the analysis, patients who were positive for certain HLA genotypes and treated with the highest number of doses of Diamyd® (three and four subcutaneous injections) experienced a statistically significant treatment effect of approximately 60%